Compare SIDU & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIDU | IMUX |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.1M | 85.8M |
| IPO Year | 2021 | N/A |
| Metric | SIDU | IMUX |
|---|---|---|
| Price | $2.62 | $0.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 47.3M | 1.5M |
| Earning Date | 11-14-2025 | 02-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,623,538.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $100.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.63 | $0.52 |
| 52 Week High | $6.75 | $1.39 |
| Indicator | SIDU | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 69.25 | 29.05 |
| Support Level | $1.77 | $0.55 |
| Resistance Level | $3.38 | $0.60 |
| Average True Range (ATR) | 0.43 | 0.04 |
| MACD | 0.18 | -0.01 |
| Stochastic Oscillator | 71.74 | 2.01 |
Sidus Space Inc is a Space and Defense as-a-Service company focused on providing complex space hardware, satellite/spacecraft design, manufacture, launch, and data solutions for both government and commercial in-space missions for all destinations through the solar system. This includes a Space-based infrastructure of multi-mission satellites with hyperspectral, multi-spectral, and other sensors to provide monitoring services and solutions to multiple sectors and industries. The company supports Commercial Space, Aerospace, Defense, Underwater Marine, and other commercial and government customers.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.